The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis

To investigate cardiac signalling pathways connecting substrate utilization with left ventricular remodelling in a murine pressure overload model.

• Publication year

  2022

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2022-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/dom.14814PMID 35801343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

  2021cited by this paper
• Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?

  2021cited by this paper
• Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases

  2021cited by this paper
• The complex network of mTOR signaling in the heart.

  2021cited by this paper
• Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors

  2020cited by this paper
• SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

  2020influential reference
• Cachexia, muscle wasting, and frailty in cardiovascular disease

  2020cited by this paper
• SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

  2020cited by this paper
• Empagliflozin improves left ventricular diastolic function of db/db mice.

  2020cited by this paper
• Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients

  2019cited by this paper
• SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

  2019cited by this paper
• Lin28a Regulates Pathological Cardiac Hypertrophic Growth through Pck2‐mediated Enhancement of Anabolic Synthesis

  2019cited by this paper
• Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

  2019influential reference
• Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction

  2019cited by this paper
• Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction

  2019cited by this paper
• Metabolic remodelling in heart failure

  2018influential reference
• Endoplasmic reticulum stress in the heart: insights into mechanisms and drug targets

  2018cited by this paper
• New Insights Into the Role of mTOR Signaling in the Cardiovascular System.

  2018cited by this paper
• Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes

  2017cited by this paper
• Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.

  2017cited by this paper
• The Failing Heart Relies on Ketone Bodies as a Fuel

  2016cited by this paper
• mTOR, cardiomyocytes and inflammation in cardiac hypertrophy.

  2016cited by this paper
• Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure

  2016cited by this paper
• Targeting myocardial substrate metabolism in heart failure: potential for new therapies

  2012cited by this paper
• AKT signalling in the failing heart

  2011cited by this paper
• Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents.

  2010cited by this paper

• Serinc2 antagonizes pressure overload-induced cardiac hypertrophy via regulating the amino acid/mTORC1 signaling pathway.

  2025cites this paper
• Molecular aspects of SGLT2 inhibitor interactions in myocardial failure

  2025cites this paper
• Therapeutic Potential of Ertugliflozin in Renal Ischemia/Reperfusion Injury by Modulating Nrf2 and Necroptosis Pathways: A Preclinical Study in Rats

  2025cites this paper
• Redox and apoptosis modulation by telmisartan, ertugliflozin, and omaveloxolone in a rat model of global cerebral ischemia/reperfusion injury

  2025cites this paper
• Targeting the Immunometabolism Interface: A Novel Strategy for IPF Therapy.

  2025cites this paper
• Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors

  2025cites this paper
• Ertugliflozin ameliorates experimentally-induced colitis in rats by regulating the interplay between M1/M2 macrophage polarization, tight junction proteins, and MicroRNA 155 expression.

  2025cites this paper
• SGLT2 inhibitors and cardiac fibrosis: A comprehensive review.

  2025cites this paper
• Ertugliflozin mitigates renal ischemia-reperfusion injury through the downregulation of HIF-1α expression.

  2025cites this paper
• Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model

  2025cites this paper
• Development of a Mouse Model of Uremic Cardiomyopathy: Investigating the Impact of Chronic Kidney Disease on Cardiac Function and Signaling Pathway

  2025influential citation
• A comprehensive review of the efficacy and safety of ertugliflozin

  2025cites this paper
• The Extracellular Matrix and Cardiac Pressure Overload: Focus on Novel Treatment Targets

  2024cites this paper
• Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)

  2024cites this paper
• SGLT-2 inhibitors as novel treatments of multiple organ fibrosis

  2024cites this paper
• Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors.

  2024cites this paper
• Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials

  2024cites this paper
• Implications of endoplasmic reticulum stress and autophagy in aging and cardiovascular diseases

  2024cites this paper
• SGLT2 inhibitors: how do they affect the cardiac cells

  2024cites this paper
• Progress in the Treatment of Pathological Cardiac Remodeling with Sodium-Glucose Cotransporter 2 Inhibitors

  2024cites this paper
• SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis

  2024cites this paper
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases

  2024cites this paper
• Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside

  2024cites this paper
• SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism

  2023cites this paper
• The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins

  2023cites this paper
• Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity

  2023cites this paper
• Acquired cardiovascular disease in adults with congenital heart disease.

  2023cites this paper
• Current status and emerging trends of cardiac metabolism from the past 20 years: A bibliometric study

  2023cites this paper
• New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling.

  2023cites this paper
• Ketones and the Heart: Metabolic Principles and Therapeutic Implications

  2023cites this paper
• The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation.

  2023cites this paper
• Research progress on post-translational modification of proteins and cardiovascular diseases

  2023cites this paper
• Improvement of Global Longitudinal Strain and Myocardial Work in Type 2 Diabetes Patients on Sodium–Glucose Cotransporter 2 Inhibitors Therapy

  2023cites this paper
• Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later

  2023cites this paper
• 2,8-Dihydroxyadenine-induced nephropathy causes hexosylceramide accumulation with increased mTOR signaling, reduced levels of protective SirT3 expression and impaired renal mitochondrial function.

  2023cites this paper
• SGLT2 inhibitors in heart failure: insights from plasma proteomics.

  2022cites this paper
• Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

  2022cites this paper
• Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme

  2022cites this paper
• Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms

  2022cites this paper
• Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention

  2022cites this paper
• The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy

  2022cites this paper
• The Effect of High-Intensity Interval Training (HIIT) on Reticulophagy-Related Proteins in the Left Ventricle of the Heart of Rats with Type 2 Diabetes

  year unknowncites this paper